Aptus Capital Advisors LLC Acquires Shares of 2,327 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Aptus Capital Advisors LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, HoldingsChannel reports. The firm bought 2,327 shares of the biotechnology company’s stock, valued at approximately $283,000.

Other large investors have also recently bought and sold shares of the company. Manchester Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 216 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a report on Wednesday. Deutsche Bank Aktiengesellschaft lowered their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Wells Fargo & Company cut their price target on Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday. Guggenheim lowered their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Oppenheimer cut their target price on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating for the company in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $131.22.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $36.52 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of 29.22 and a beta of 0.85. Sarepta Therapeutics, Inc. has a one year low of $35.46 and a one year high of $173.25. The company has a 50 day moving average price of $68.17 and a 200 day moving average price of $101.49.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. The company’s quarterly revenue was up 80.2% on a year-over-year basis. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.